Journal ArticleDOI
Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures
Wilma Barcellini,Juri Alessandro Giannotta,Juri Alessandro Giannotta,Bruno Fattizzo,Bruno Fattizzo +4 more
Reads0
Chats0
TLDR
The severity of anemia at onset correlated with the recurrence of relapses, refractoriness, and fatal outcome reflects the presence of several mechanisms involved in AIHA, i.e. highly pathogenic antibodies, complement activation, and failure of marrow compensation.Abstract:
Autoimmune hemolytic anemia (AIHA) is due to autoantibodies against erythrocytes that may arise either because of primary tolerance breakage or along with several associated conditions, including g...read more
Citations
More filters
Journal ArticleDOI
New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1.
TL;DR: A comprehensive review of the main clinical characteristics, diagnosis, and pathogenic mechanisms of AIHA are provided, along with classic and new therapeutic approaches.
Journal ArticleDOI
How I treat warm autoimmune hemolytic anemia.
Wilma Barcellini,Bruno Fattizzo +1 more
TL;DR: Warm autoimmune hemolytic anemia (wAIHA) is caused by increased erythrocyte destruction by immunoglobulin G (IgG) autoantibodies, with or without complement activation as discussed by the authors.
Journal ArticleDOI
Autoimmune hemolytic anemia: current knowledge and perspectives
Sylwia Sulimiera Michalak,Anna Olewicz-Gawlik,Anna Olewicz-Gawlik,Joanna Rupa-Matysek,Edyta Wolny-Rokicka,Elżbieta Nowakowska,Lidia Gil +6 more
TL;DR: Changes in classification and progress in understanding the pathogenesis and treatment of autoimmune hemolytic anemia are brought about, although there are still many issues to be resolved, particularly concerning the impact of age-associated changes to immunity.
Journal ArticleDOI
Autoimmune Complications in Hematologic Neoplasms.
TL;DR: In this paper, the authors analyzed the available literature of the last 30 years regarding the occurrence of AICy/AID in different onco-hematologic conditions, including chronic lymphocytic leukemia (CLL), lymphomas, multiple myeloma, myelodysplastic syndromes (MDS), chronic myelomonocytic leucocyte leukemia (CMML), myeloproliferative neoplasms, and acute leukemias.
Journal ArticleDOI
Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature
Bruno Fattizzo,Bruno Fattizzo,Raffaella Pasquale,Valentina Bellani,Valentina Bellani,Wilma Barcellini,Austin G. Kulasekararaj +6 more
TL;DR: In this article, the authors describe four patients (2 with PNH and 2 with CAD) who experienced hemolytic flares after either COVID-19 infection or SARS-Cov2 vaccine and provide a review of the most recent literature.
References
More filters
Journal ArticleDOI
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R. Furman,Jeff P. Sharman,Steven Coutre,Bruce D. Cheson,John M. Pagel,Peter Hillmen,Jacqueline C. Barrientos,Andrew D. Zelenetz,Thomas J. Kipps,Ian W. Flinn,Paolo Ghia,Herbert Eradat,Thomas J. Ervin,Nicole Lamanna,Bertrand Coiffier,Andrew R. Pettitt,Shuo Ma,Stephan Stilgenbauer,Paula Cramer,Maria Aiello,Dave Johnson,Langdon L. Miller,Daniel Li,Thomas Jahn,Roger Dansey,Michael Hallek,Susan O'Brien +26 more
TL;DR: The combination of idelalisib and rituximab, as compared with placebo and r ituximabs, significantly improved progression-free survival, response rate, and overall survival among patients with relapsed CLL who were less able to undergo chemotherapy.
Journal ArticleDOI
Autoimmune hemolytic anemia
TL;DR: This review discusses the demographics, etiology, clinical presentation, laboratory evaluation, and treatment options of autoimmune hemolytic anemia, which includes warm AIHA, cold agglutinin syndrome, paroxysmal cold hemoglobinuria, mixed‐type AIH, and drug‐induced AIHA.
Journal ArticleDOI
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Kirsten Fischer,Jasmin Bahlo,Anna-Maria Fink,Valentin Goede,Carmen D. Herling,Paula Cramer,Petra Langerbeins,Julia von Tresckow,Anja Engelke,Christian Maurer,Gabor Kovacs,Marco Herling,Eugen Tausch,Karl Anton Kreuzer,Barbara Eichhorst,Sebastian Böttcher,John F. Seymour,Paolo Ghia,Paula Marlton,Paula Marlton,Michael Kneba,Clemens M. Wendtner,Hartmut Döhner,Stephan Stilgenbauer,Michael Hallek +24 more
TL;DR: First-line chemoimmunotherapy with FCR induces long-term remissions and highly relevant improvement in OS in specific genetic subgroups of fit patients with CLL, in particular those with IGHV MUT.
Journal ArticleDOI
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations
Kostas Stamatopoulos,Chrysoula Belessi,Carol Moreno,Myriam Boudjograh,Giuseppe Guida,Tatjana Smilevska,Lynda Belhoul,Stefania Stella,Niki Stavroyianni,Marta Crespo,Anastasia Hadzidimitriou,Laurent Sutton,Francesc Bosch,Nikolaos Laoutaris,Achilles Anagnostopoulos,Emili Montserrat,Athanasios Fassas,Guillaume Dighiero,Federico Caligaris-Cappio,Hélène Merle-Béral,Paolo Ghia,Frederic Davi +21 more
TL;DR: It is suggested that a particular antigen-binding site can be critical in determining the clinical features and outcome for at least some CLL patients.
Journal ArticleDOI
Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects
Charlotte Schwab,Annemarie Gabrysch,Peter Olbrich,Virginia Patiño,Klaus Warnatz,Daniel Wolff,Akihiro Hoshino,Masao Kobayashi,Kohsuke Imai,Masatoshi Takagi,Ingunn Dybedal,Jamanda A. Haddock,David M. Sansom,José Manuel Lucena,Maximilian Seidl,Annette Schmitt-Graeff,Veronika Reiser,Florian Emmerich,Natalie Frede,Alla Bulashevska,Ulrich Salzer,Desirée Schubert,Seiichi Hayakawa,Satoshi Okada,Maria Kanariou,Zeynep Yesim Kucuk,Hugo Chapdelaine,Lenka Petruzelkova,Zdenek Sumnik,Anna Sediva,Mary Slatter,Peter D. Arkwright,Andrew J. Cant,Hanns-Martin Lorenz,Thomas Giese,Vassilios Lougaris,Alessandro Plebani,Christina Price,Kathleen E. Sullivan,Michel Moutschen,Jiri Litzman,Tomáš Freiberger,Frank L. van de Veerdonk,Mike Recher,Michael H. Albert,Fabian Hauck,Suranjith L. Seneviratne,Jana Pachlopnik Schmid,Antonios G.A. Kolios,Gary Unglik,Christian Klemann,Christian Klemann,Carsten Speckmann,Stephan Ehl,Alan M. Leichtner,Richard S. Blumberg,Andre Franke,Scott B. Snapper,Sebastian Zeissig,Sebastian Zeissig,Sebastian Zeissig,Charlotte Cunningham-Rundles,Lisa Giulino-Roth,Olivier Elemento,Gregor Dückers,Tim Niehues,Eva Fronkova,Veronika Kanderova,Craig D. Platt,Janet Chou,Talal A. Chatila,Raif S. Geha,Elizabeth M. McDermott,Su Bunn,Monika Kurzai,Ansgar Schulz,Laia Alsina,Ferran Casals,Angela Deyà-Martínez,Sophie Hambleton,Hirokazu Kanegane,Kjetil Taskén,Olaf Neth,Bodo Grimbacher,Bodo Grimbacher +84 more
TL;DR: The penetrance, clinical features, laboratory values, and outcomes of treatment options were assessed in a worldwide cohort of CTLA4 mutation carriers, finding affected mutation carriers with CTLA‐4 insufficiency can present in any medical specialty.